Switzerland (CH)

NOVEL MUTATIONS AND FINDINGS IN A COHORT OF MCLEOD NEUROACANTHOCYTOSIS, AN X-LINKED HD PHENOCOPY (2021) Peikert K, Schlotter-Weigel B, Montagnese F, Reilich P, Saft C, Marxreiter F, Kohl Z, et al. Conference contribution A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP) (2021) Binder M, Meyer O, Rummel M, Nimmerjahn F, Tesanovic T, Sauer T, Matzdorff A Conference contribution Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis (2021) Böttcher M, Bruns H, Lu J, Chartomatsidou E, Papakonstantinou N, Mentz K, Büttner-Herold M, et al. Conference contribution Long-term Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes - Interim Analysis of the RELIANCE Registry (2021) Kuemmerle-Deschner J, Henes J, Kortus-Goetze B, Kallinich T, Oommen PT, Rech J, Weller-Heinemann F, et al. Conference contribution Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients (2021) Rech J, Hueber A, Ostergaard M, Tascilar K, Hagen M, Mendez LV, Kleyer A, et al. Conference contribution Influence of Canakinumab Dosing on Long-term Efficacy and Safety in Patients with Cryopyrin-associated Periodic Syndromes (CAPS)-30-months Interim Analysis of the RELIANCE Registry (2021) Kuemmerle-Deschner J, Kortus-Goetze B, Oommen PT, Janda A, Rech J, Kallinich T, Weller-Heinemann F, et al. Conference contribution Clusters of Psoriatic Arthritis Patients at Baseline Based on Different Ultrasound Detected Synovitis: Exploratory Analysis from a Phase III Study (2021) D'Agostino MA, Schett G, Gaillez C, Conaghan P, Naredo E, Carron P, Burgos-Vargas R, et al. Conference contribution Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study (2021) D'Agostino MA, Schett G, Gaillez C, Guerrero C, Hanova P, Cazenave T, Stoenoiu MS, et al. Conference contribution Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial (2021) Venhoff N, Schmidt W, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, et al. Conference contribution Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study (2021) Kaeley G, Schett G, Conaghan P, Mcgonagle D, Behrens F, Goupille P, Gaillez C, et al. Conference contribution